Orbit Discovery

Executive Summary

Orbit Discovery is a UK-based private biotech specializing in the discovery of peptide conjugates for precise radionuclide delivery, leveraging its proprietary bead-based flow cytometry platform to identify high-affinity peptides targeting tumor-specific antigens. Founded in 2015 and headquartered in Oxford, the company aims to enhance targeting specificity while minimizing off-target effects, addressing key challenges in radiopharmaceutical development for targeted radionuclide therapy. Its diverse peptide libraries and unique screening approach differentiate it from traditional antibody-based or small-molecule radioconjugates. Although still in early stages with no disclosed funding or pipeline details, Orbit Discovery operates in the rapidly growing field of theranostics and peptide-drug conjugates, presenting potential for breakthroughs in cancer treatment. The company's technology could enable safer and more effective delivery of therapeutic radionuclides, positioning it as a candidate for partnerships with radiopharmaceutical developers or larger pharma seeking innovative targeting moieties. However, limited public information on progress, funding, or clinical milestones warrants a cautious outlook, pending validation of its platform through preclinical data or strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q1 2027Lead Candidate IND-Enabling Studies Initiation30% success
• H2 2026Strategic Partnership with Pharmaceutical Company for Radioconjugate Development40% success